dc.date.accessioned2019-07-04T17:00:16Z
dc.date.available2019-07-04T17:00:16Z
dc.date.created2019-07-04T17:00:16Z
dc.date.issued2019
dc.identifierhttps://hdl.handle.net/20.500.12866/6824
dc.identifierhttps://doi.org/10.1016/j.jacep.2018.10.016
dc.description.abstractObjectives: This study hypothesized that paroxysmal atrial fibrillation (PAF) reflects the presence of a more severe cardiac hypertrophic cardiomyopathy (HCM) phenotype. Background: HCM is characterized by myocyte hypertrophy, fibrosis, and a high prevalence of PAF. It is currently unresolved whether atrial fibrillation (AF) is a marker or a mediator of adverse outcomes in HCM. Methods: This study retrospectively examined 45 HCM patients who underwent cardiovascular magnetic resonance (CMR) imaging in sinus rhythm. The function of all 4 cardiac chambers was assessed, as well as late gadolinium enhancement (LGE) in the left atrium (LA) and left ventricle (LV), as indicators of fibrosis. A fat-saturated, 3-dimensional inversion recovery–prepared, fast-spoiled, gradient-recalled echo sequence, and the image intensity ratio method were used to measure LA-LGE; LGE in the LV was quantified using a semi-automated threshold technique. Results: HCM patients (n = 45) were divided into 2 groups (PAF, no AF) based on history of PAF. All HCM patients had LGE in the LA posterior wall. The PAF group (n = 18) had higher LA volume, a lower LA ejection fraction, a lower global peak longitudinal LA strain (PLAS), and a higher amount of LA-LGE compared with the no AF group (n = 27). A modest inverse association was noted between the LA ejection fraction, PLAS, and LA-LGE; a positive association was present between LV-LGE and LA-LGE. The PAF group had lower ejection fractions in the LV, right atrium, and right ventricle compared with those in the no AF group. Conclusions: PAF is associated with a greater degree of structural LA remodeling and global myopathy, which suggests a more severe cardiac HCM phenotype.
dc.languageeng
dc.publisherElsevier
dc.relationJACC. Clinical Electrophysiology
dc.relation2405-5018
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjecthuman
dc.subjectadult
dc.subjectfemale
dc.subjectmale
dc.subjectmiddle aged
dc.subjectArticle
dc.subjectpriority journal
dc.subjectadverse outcome
dc.subjectdisease burden
dc.subjectcontrolled study
dc.subjectprevalence
dc.subjectphenotype
dc.subjectretrospective study
dc.subjectbeta adrenergic receptor blocking agent
dc.subjectclinical article
dc.subjectgadolinium
dc.subjectthree dimensional imaging
dc.subjectantiarrhythmic agent
dc.subjectcardiovascular magnetic resonance
dc.subjectcardiovascular magnetic resonance imaging
dc.subjectcardiovascular parameters
dc.subjectheart ejection fraction
dc.subjectheart left atrium
dc.subjectheart left ventricle
dc.subjectheart right atrium
dc.subjectheart right ventricle
dc.subjectHolter monitoring
dc.subjecthypertrophic cardiomyopathy
dc.subjectlate gadolinium enhancement in the left atrium
dc.subjectparoxysmal atrial fibrillation
dc.subjectradiological parameters
dc.subjectsinus rhythm
dc.titleHypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución